TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04848077

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step count increase with the use of a motivational smartphone application
Description: All participants will be given access to an application installed on the participants' own smartphone: the STEPWISE app. The STEPWISE app will encourage participants to increase their long-term physical activity (1 year). Different treatment arms will receive different physical activity goals. Participants will get feedback and support via the smartphone app, that stimulates them to reach their individual physical activity goal (i.e. target percentage increase in stepcount).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step count increase with the use of a motivational smartphone application
Description: All participants will be given access to an application installed on the participants' own smartphone: the STEPWISE app. The STEPWISE app will encourage participants to increase their long-term physical activity (1 year). Different treatment arms will receive different physical activity goals. Participants will get feedback and support via the smartphone app, that stimulates them to reach their individual physical activity goal (i.e. target percentage increase in stepcount).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step count increase with the use of a motivational smartphone application
Description: All participants will be given access to an application installed on the participants' own smartphone: the STEPWISE app. The STEPWISE app will encourage participants to increase their long-term physical activity (1 year). Different treatment arms will receive different physical activity goals. Participants will get feedback and support via the smartphone app, that stimulates them to reach their individual physical activity goal (i.e. target percentage increase in stepcount).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step count increase with the use of a motivational smartphone application
Description: All participants will be given access to an application installed on the participants' own smartphone: the STEPWISE app. The STEPWISE app will encourage participants to increase their long-term physical activity (1 year). Different treatment arms will receive different physical activity goals. Participants will get feedback and support via the smartphone app, that stimulates them to reach their individual physical activity goal (i.e. target percentage increase in stepcount).
Study: NCT04859569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01011
Description: subcutaneously (SC) once every 4 weeks (Q4W)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY01011
Description: subcutaneously (SC) once every 4 weeks (Q4W)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xgeva®
Description: subcutaneously (SC) once every 4 weeks (Q4W)
Study: NCT06250244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-LNC1011
Description: \[177Lu\]Lu-LNC1011 is a novel long-circulating PSMA therapeutic probe.
Study: NCT04865341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB
Description: Intervention content will be focused on the Information-Motivation-Behavioral Skills (IMB) model. We plan to incorporate previously developed content as much as possible and will include professionally produced videos about HIV testing and PrEP and other resources. We believe our approach of guiding YMSM through intervention modules based on theory will help improve content retention/use and ultimately influence constructs posited to result in behavior change. We foresee using multiple forms of attention-matched material, media, and programming to engage (and retain engagement) of YMSM throughout the brief single-session intervention (45-60 minutes).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Information-Only Control
Description: Intervention content will be focused on the information construct of the Information-Motivation-Behavioral Skills (IMB) model. We plan to incorporate previously developed content as much as possible and will include professionally produced videos about HIV testing and PrEP and other resources. We believe our approach of guiding YMSM through intervention modules based on theory will help improve content retention/use and ultimately influence constructs posited to result in behavior change. We foresee using multiple forms of attention-matched material, media, and programming to engage (and retain engagement) of YMSM throughout the brief single-session intervention (45-60 minutes).
Study: NCT06151379

Intervention type: OTHER
Intervention: Neoadjuvant therapy
Description: To measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.

Intervention type: OTHER
Intervention: Neoadjuvant therapy
Description: To measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
Study: NCT05366855

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Imsidolimab
Description: Solution for infusion; Solution for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Imsidolimab
Description: Solution for infusion; Solution for injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection
Study: NCT05063253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103
Description: TG103 injection, SC, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103
Description: TG103 injection, SC, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103
Description: TG103 injection, SC, once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, SC, once weekly
Study: NCT06312709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: teleABLE (telehealth-delivered Activating Behavior for Lasting Engagement)
Description: teleABLE uses behavioral activation to build personally meaningful non-sedentary throughout the day. This is accomplished using a global strategy, the ICAN Planning Process, which guides participants through activity scheduling, activity monitoring, self-assessment, and collaborative problem solving.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health Education provides information about stroke using factsheets from the American Heart Association and reflection questions that support participants in applying the information.
Study: NCT05143697

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wellness Coaching for Families and Kids
Description: The investigators propose to conduct a cluster-randomized pragmatic trial in 49 pediatric clinics in Kaiser Permanente Southern California (KPSC), to test the effectiveness of mBMI2Kids (a modified version of the BMI2 interven-tion) in pediatric clinics (randomization unit). Clinics serve over 45,000 children aged 2-8 yrs who are obese and have high racial/ethnic and socioeconomic diversity (53% Hispanic; 23% state-subsidized insurance). Clinics will be randomized into either 24 intervention or 25 usual care + attention control (enrolling 6,600 children). KP's long-standing electronic medical record (EMR) and stable membership, a research team embedded in care, existing team of lifestyle coaches, and ability to rapidly disseminate findings makes us uniquely positioned to conduct this study.
Study: NCT04976244

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal injection to the regimen pro re nata

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal injection to the regimen pro re nata
Study: NCT06442007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation - single session intervention (BA-SSI)
Description: Single session intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4-session Mindset intervention
Description: This is comprised of 4 sessions.
Study: NCT06381544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy application
Description: Applying lemon, orange and frankincense oils via inhalation
Study: NCT05041010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu2000KWL group
Description: 1st infusion of 750mg in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 ± 1 hours, twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: 1st infusion of the same volume of saline in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 ± 1 hours, twice a day
Study: NCT05037630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-guided Digital Tool for Problematic Alcohol Use
Description: See arm/group-description
Study: NCT05036226

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Metformin, Sirolimus
Description: Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Metformin, Sirolimus, Dasatanib
Description: Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Dasatinib 20mg daily

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir
Description: Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib
Description: Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily Dasatanib 20mg daily

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir
Description: Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib
Description: Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily Dasatanib 20mg daily
Study: NCT06228391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV ketamine
Description: Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg for 40 minutes twice a week for 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Subjects will receive a single infusion of midazolam at 0.045mg/kg for 40 minutes twice a week for 3 weeks.
Study: NCT04972305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and ergonomics
Description: 12 week exercise and fit bike

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomics
Description: Fit bike
Study: NCT05565495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the contents of hydromorphone and hydromorphone-3-glucuronide (main metabolite) were detected by quantitative liquid chromatography tandem mass spectrometry, and then A population pharmacokinetic model of hydromorphone in patients under ECMO was established.
Study: NCT06218160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone combined with ropivacaine
Description: 1mg hydromorphone was added to 0.375% ropivacaine for a total of 30ml to perform quadrat block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: A mixture of 0.375% ropivacaine for a total of 30ml was used for quadrate block
Study: NCT05658432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise via telehealth
Description: Same as arm/group description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise unsupervised
Description: Same as arm/group description
Study: NCT05922384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL-7SHRNA injection solution
Description: Patients continue to receive HAART throughout treatment until meet the criteria of interruption of HAART.
Study: NCT05889975

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: interdental brush
Description: cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single tufted brush
Description: cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
Study: NCT05090670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incrediwear Germanium-Embedded Knee Brace following Knee Arthroscopy
Description: Germanium-Embedded Knee Brace will be applied to the effected limb following Knee Arthroscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Replica Knee Brace
Description: Replica Knee brace will be applied to the effected limb following Knee Arthroscopy
Study: NCT05501977

Intervention type: PROCEDURE
Intervention: thoracotomy
Description: thoracic surgery for pulmonary diseases

Intervention type: PROCEDURE
Intervention: thoracotomy
Description: thoracic surgery for pulmonary diseases
Study: NCT05315505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maintenance programme
Description: Continuous educational support, exercise training, behaviour change intervention, and self-management.~Maintenance home-based pulmonary rehabilitation programme for ten months with alternate supervision

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: No maintenance programme, and the patient has the usual follow-up and medical appointments
Study: NCT05833490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive Peripheral Magnetic Stimulation (rPMS)
Description: Repetitive Peripheral Magnetic Stimulation (rPMS) is an external device that delivers repetitive pulsed magnetic fields of sufficient magnitude, will be applied on the tibialis anterior muscle belly at \~ 10% of motor threshold, in order to induce neural action potentials in the lower extremities.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Priming
Description: Sham Priming using the Repetitive Peripheral Magnetic Stimulation (rPMS), it will be applied on the dorsal part of the foot with a minimal intensity at 5% of maximum stimulator output, that is of insufficient magnitude to induce changes in the muscle or nerves of lower extremities.
Study: NCT06329973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib in combination with Sintilimab and CAPEOX
Description: Different doses of fruquintinib combined with sintilimab and CAPEOX
Study: NCT05889975

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: water irrigator
Description: using water irrigator after manual tooth brushing twice daily with 300ml distal water placed in its container. The patients instructed to use the entire 300ml during each irrigation for 30 days
Study: NCT04419272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 10mg twice per day, at 8am and 12pm, for one week, then increased to 20mg twice daily, at 8am and 12pm, for the next 7 weeks during the double-blinded period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: When assigned to receive the placebo during the double-blinded period, subjects will be given a sugar pill for 8 weeks. The sugar pill will be taken twice per day, at 8am and 12pm.

Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate
Description: During the open-label extension phase, dosing will begin at 10mg twice per day, at 8am and 12pm, for one week. The dosage will then increase to 20mg twice daily, at 8am and 12pm, for the next 7 weeks.
Study: NCT05553327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation
Description: * Physical state: individualised physical status will be evaluated by a physiotherapist. A specific training program and pelvic floor exercises sessions will be led by a physiotherapist.~* Nutritional state: individual nutritional status will be evaluated by a nutritionist and intervention will be done if applicable. A nutrition group session will be held.~* Mental health: mindfulness group sessions led by psychologists will be held.
Study: NCT06388772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QHRD106 Injection
Description: 250IU\~8400IU,pegylated(PEG)-tissue kallikrein-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study: NCT05843409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Description: Mindfulness-based stress reduction may be associated with short-term effects on pain intensity and physical functioning. Patients will be randomized into 2 groups. The experimental group will receive MBSR sessions, with the frequency and duration specified in the study protocol. The sessions will be free and carried out by expert staff
Study: NCT06142266

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise rehabilitation program
Description: This program will consist of twice-weekly supervised exercise sessions, including aerobic training and resistance exercises targeting the lower limbs for 12-week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise rehabilitation program
Description: This program will consist of twice-weekly supervised exercise sessions, including aerobic training and resistance exercises targeting the lower limbs for 12-week
Study: NCT05617430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC
Description: Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.~Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg IV d1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Biosimilar IBI305
Description: 7.5mg/kg IV d1, Q3W
Study: NCT06131489

Intervention type: OTHER
Intervention: Segmental bowel resection combined with the DEP regimen
Description: Segmental bowel resection combined with liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles
Study: NCT05253495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOC Group B
Description: Cyclophosphamide 300 mg x1; dexamethasone x 7; vincristine x1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pv-COMRAD 1 and 2 Group B
Description: polatuzumab vedotin x1; dexamethasone x 5; vincristine x1, cyclophosphamide x 3; doxorubicin x1; methotrexate x; rituximab 2x; ITT x1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pv-R-CYM 1 and 2 Group B
Description: polatuzumab vedotin x 1; methotrexate x 1; rituximab x 1; cytarabine x 5;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOC Group C
Description: cyclophosphamide x 1, dexamethasone x 5; vincristine x1; IT triples x 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD CPR 1 and 2
Description: methotrexate x 1; dexamethasone x 5; polatuzumab Vedotin x 1, cyclophosphamide x 3; doxorubicin x 1; rituximab x2; IT triples x 2 in induction 1, IT triples x 2 in induction 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pv-R CYVE 1 and 2
Description: Polatuzumab Vedotin x 1; Rituximab x 1; Cytarabine x 5; Etoposide x4;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pv-R CYVE-MTX 1 and 2
Description: Polatuzumab Vedotin x 1; Rituximab x 1; Cytarabine x 5; Etoposide x4; high dose cytarabine x4; high dose methotrexate x 1 (only consolidation 1); IT triples x 2 (only 1 in consolidation 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD CP
Description: dexamethasone x1; polatuzumab vedotin x 1; cyclophosphamide x 2; doxorubicin x 1; high dose methotrexate x 1; IT triples x 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pv-Cytarabine/etoposide
Description: polatuzumab vedotin x 1; cytarabine x 5; etoposide x 3;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD CP
Description: polatuzumab vedotin x 1; cyclophosphamide x2; doxorubicin x 2;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bv-AVD-R 1 and 2: COHORT IIa
Description: brentuximab vedotin x 2; doxorubicin x 2; vinblastine x 2; dacarbazine 2x; rituximab x 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bv-NVD-R, Cycle 1-2
Description: brentuximab vedotin x 2; nivolumab x 2; vinblastine x2; dacarbazine x 2; rituximab x 2;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bv-NVD-R, Cycle 1-4 SER
Description: brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; rituximab x 2;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bv-AVD-R
Description: Brentuximab vedotin x2; doxorubicin x2; vinblastine x 2; dacarbazine x 2; rituximab x2;
Study: NCT05352646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous memory lymphocyte Injection (NewishT), low-dose group
Description: Recruited participants in low-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 4 weeks, a total of 2 times.
Study: NCT05253495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bv-NVD-R, Cycle 1-4 RER
Description: brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bv-NAVD-R, Cycle 1-2
Description: brentuximab vedotin x 2; nivolumab x 2; doxorubicin x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved Site Radiation Therapy
Description: 21 Gy in 14 fractions of 1.50 Gy per day. The treatment will be given 5 days per week. All fields shall be treated once each day. The total elapsed treatment time will be 2.8 weeks (14 sessions) for each field.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved Site Radiation Therapy
Description: 21 Gy in 14 fractions of 1.50 Gy per day. The treatment will be given 5 days per week. All fields shall be treated once each day. The total elapsed treatment time will be 2.8 weeks (14 sessions) for each field.